“Novel Compounded Sublingual Buprenorphine Solution Remains Stable for Neonatal Opioid Withdrawal Syndrome Treatment”

https://pubmed.ncbi.nlm.nih.gov/38094678

This study found that a novel, compounded sublingual buprenorphine solution free of alcohol, sugars, and preservatives remained stable with minimal variation in drug concentration for up to 14 days when stored in refrigeration, potentially offering a safer option for treating neonatal opioid withdrawal syndrome.